Johnson Pharmacare Limited reported a net loss of ₹5,573.39 lakh for the financial year ended March 31, 2026, significantly widening from a net loss of ₹58.38 lakh in the previous year. The company's total income for FY26 stood at ₹158.10 lakh, while total expenses surged to ₹4,304.49 lakh, primarily driven by other expenses amounting to ₹4,276.48 lakh. The board approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 27, 2026.

The standalone financial statements were subject to a qualified opinion from the statutory auditor, VRSK & Associates, due to non-provision of interest on loans and non-compliance with Indian Accounting Standards (Ind AS). The auditor noted that the company is not capable of meeting its liabilities as and when they fall due within a period of one year from the balance sheet date. Additionally, the company reported cash losses of ₹11,123.52 lakh for the current financial year.

Financial Performance

The company recorded a basic and diluted earnings per share (EPS) of (₹1.01) for FY26, a significant decline from (₹0.01) in the previous year. The balance sheet reflects total assets of ₹2,203.11 lakh as of March 31, 2026, a decrease from ₹5,792.59 lakh in the prior year. Non-current investments stood at ₹1,972.50 lakh, while borrowings amounted to ₹2,140.19 lakh.

Board and Governance Updates

During the meeting, the board took note of the resignations of two directors effective April 17, 2026. Rajendra Prasad, Additional Non-Executive Director, and Umesh Kumar, Additional Executive Director, both resigned citing personal reasons and unavoidable circumstances. The board also confirmed that Regulation 32 of the SEBI (LODR) Regulations, 2015, regarding deviation or variation, is not applicable to the company as it has not issued equity shares via preferential issue.

The trading window, which closed on April 1, 2026, will remain shut until 48 hours after the declaration of the audited financial results. The filing was signed by Nand Kishor Ray, Additional Director, on behalf of the board.

Johnson Pharmacare Limited has disclosed that it did not undertake any transactions with related parties during the financial year ended March 31, 2026. In a regulatory filing submitted to BSE on May 27, 2026, the company confirmed that while the provisions for Related Party Transactions (RPT) are applicable, no such transactions were entered into during the reporting period. Consequently, the disclosure of RPTs for the year is not applicable.

The filing was made pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015. The disclosure follows the format specified in SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021. The submission was signed by Nand Kishor Ray, Additional Director of the company.

The company provided a detailed table in the filing to declare the status of these transactions. The table covers various aspects, including details of the counterparty, the nature of the relationship, and the value of transactions. It also includes columns for financial indebtedness and details of loans or investments, should any have existed.

The table confirms that all relevant fields, including financial indebtedness, nature of loans, and interest rates, were nil for the period. This indicates that the company maintained no outstanding dues or financial engagements with related parties throughout FY26.